jueves, 19 de noviembre de 2026

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide?utm_medium=email&utm_source=govdelivery The GRDP launched on Oct. 30, with a President's Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. This is an especially meaningful starting point given PEPFAR's life-saving mission to combat HIV/AIDS in some of the world's most vulnerable populations. The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. However, the FDA intends to expand the GRDP in January 2027 to all novel drug and biologics (New Molecular Entity New Drug Applications and 351(a) Biologics License Applications), dramatically broadening the program's reach and impact. The FDA also intends to launch a pathway in early 2027 to expedite an applicant’s ability to request their minimally redacted action packages for approved and licensed drugs and biologics, accelerating global access to medicines that are already on the market in the United States and have been found to be safe and effective by the FDA. The GRDP addresses one of the most persistent and consequential challenges in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources. Beyond individual product approvals, the GRDP supports global health security. Harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets, helping to ensure that the same high-quality therapies reach patients regardless of where they live, including here in the United States.

No hay comentarios:

Publicar un comentario